Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
By continuing to use our site, you agree to our Private Policy and Terms of Use.
In a Phase III study, researchers have found that tesamorelin, an analogue of a naturally occurring growth hormone-releasing factor, decreased patients' abdominal fat by 15% on average--compared to a 5% average increase for the placebo group--with minimal side effects. Results were reported in the December 6 issue of The New England Journal of Medicine. A confirmatory trial is ongoing to comply with U.S. Food and Drug Administration regulations. -------------------- Boehringer Ingelheim has reported on a three-year study that has shown protease inhibitor Aptivus, used with ritonavir, provides a superior and durable treatment response for up to three years in HIVers who had previously been treated with antiretrovirals and displayed drug resistance. -------------------- Reporting 48-week data from a Phase III clinical trial, Gilead Sciences says patients who switched from Combivir to Truvada, both in combination with Sustiva, experienced improvements in a number of treatment-related side effects, including lipoatrophy. -------------------- Studies find that antiherpes medication valacyclovir significantly reduces rectal and plasma HIV levels in study participants coinfected with HIV-1 and HSV-2. Researchers conclude, in a report in the November 15 edition of The Journal of Infectious Diseases, that herpes simplex virus suppression might provide clinical benefits to people not receiving antiretroviral therapy. -------------------- From 2000 to 2006, public and philanthropic funding for HIV vaccine and microbicide research and development almost tripled, according to a report released in December by the HIV Vaccines and Microbicides Resource Tracking Working Group, a watchdog organization. The total global investment in preventive vaccine R&D in 2006 was about $933 million, a 23% increase over 2005 levels. Microbicide R&D during the same year reached a worldwide investment of about $222 million, a 35% increase. Between 2000 and 2006, five public-sector funders and two foundations provided $183.6 million for research and development in support of new prevention options, the report found. -------------------- HIVers with CD4-cell counts of 200 or lower who use protease inhibitor Crixivan have complications with dry skin more often than participants in a study who had higher CD4 counts or who were HIV-negative, according to research reported in the October 2007 issue of the journal AIDS. -------------------- Gilead Sciences says a second late-stage trial has shown that its anti-HIV medication Viread was more effective in treating hepatitis B than Hepsera, another Gilead , which is already approved for treating liver infection in adults.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Don’t miss our latest news! Sign up today for our free newsletter.
Plus: Featured Video